Wong Raymond S M, Bakshi Kalpana, Brainsky Andres
Prince of Wales Hospital, The Chinese University of Hong Kong, Department of Medicine and Therapeutics , Hong Kong , China.
Scand J Clin Lab Invest. 2015 Jan;75(1):13-7. doi: 10.3109/00365513.2014.962597. Epub 2014 Oct 9.
An increased risk of thromboembolic events among patients with chronic immune thrombocytopenia has been reported but is still not fully understood. A thrombophilia panel (factors suspected/known to denote a thrombophilic state or indicate activation of the clotting cascade) was measured in previously treated patients with chronic immune thrombocytopenia enrolled in an eltrombopag trial to assess potential thrombophilia risk markers. Of 167 patients, 136 (81%) had abnormal levels of at least 1 known or suspected thrombosis risk marker or coagulation cascade activation marker. Six patients reported thromboembolic events, and all of these patients had at least two abnormal analytes in the thrombophilia panel. The presence of multiple baseline thrombophilia risk markers support the theory that chronic immune thrombocytopenia is a pro-thrombotic disease.
已有报道称慢性免疫性血小板减少症患者发生血栓栓塞事件的风险增加，但仍未完全明确。在一项艾曲泊帕试验中，对先前接受过治疗的慢性免疫性血小板减少症患者进行了血栓形成倾向检测（怀疑/已知表示血栓形成倾向状态或表明凝血级联激活的因素），以评估潜在的血栓形成倾向风险标志物。在167例患者中，136例（81%）至少有1种已知或疑似血栓形成风险标志物或凝血级联激活标志物水平异常。6例患者报告发生了血栓栓塞事件，所有这些患者在血栓形成倾向检测中至少有两种分析物异常。多种基线血栓形成倾向风险标志物的存在支持了慢性免疫性血小板减少症是一种促血栓形成疾病的理论。
